Objectives: To evaluate the Vidas Chlamydia (CHL) assayfor detecting C. Trachomatis with swabs and first catch urine(FCU) specimens from STD patients and high riskpopulations.Methods: A total of 383 patients were tested with tissueculture (TC), Vidas CHL and polymerase chain reaction (PCR)for C. trachomatis on male and female swabs, with Vidas CHLtesting male FCU specimens. CHL positive and equivocalresults were confirmed with a blocking assay (CHB). Truepositive were defined as either TC positive, or TC negtive butCHL and PCR positive. The performance of TC, CHL andPCR were evaluated according to this expanded goldstandard.Results: Compared with the expanded gold standard, 54 ofthe 232 male specimens were true positive results. For maleswabs, TC, CHL and PCR had sensitivities of 90.7%, 96.3%and 94.4%, and specificities of 100%, 98.3% and 97.2%,respectively. Differences were not statistically significant. Formale FCU specimens, CHL sensitivity and specificity were83.3% and 98.3%; there was little difference between theseresults and that of matched swabs. Compared with theexpanded gold standard, 28 of the 151 female swabs were truepositive; TC, CHL and PCR had sensitivities of 82.1%, 100%and 96.4%, and specificities of 100%, 98.4% and 97.6%,respectively. The difference was also not significant.Conclusions: Vidas CHL assay is very sensitive and specificfor C. trachomatis detection with swab specimens of male andfemale STD patients. For male FCU specimens, the assay alsohad high sensitivity and specificity. CHB may not be needed inthe routine detection of Chlamydia infections. Populationswith higher incidence of C.trachomatis infection.